Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study

Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-16
DOI
https://doi.org/10.3390/ijms272210277
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study

Ga‐Young Ban, Jeong‐Hee Choi, Mi‐Ae Kim, Hyun Young Lee et al.
2 links
International Journal of Molecular Sciences
SARS-CoV-2 and COVID-19 Research
article

Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study

Ga‐Young Ban, Jeong‐Hee Choi, Mi‐Ae Kim, Hyun Young Lee, Seong‐Dae Woo, H. J. Lee, Gil‐Soon Choi, Gyu Young Hur, Chang‐Gyu Jung, Young‐Min Ye, Sang‐Ha Kim, Ji-Ho Lee, Joo‐Hee Kim, Hyun Jung Jin, Young-Hee Nam, Hyo-In Rhyou, Youngsoo Lee
article en

Abstract

Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.

International Journal of Molecular SciencesVol. 27(22)
Hallym University (KR), Yonsei University (KR), Chungnam National University (KR), Korea University (KR), Korea University Medical Center (KR), Kosin University Gospel Hospital (KR), Sacred Heart Hospital (US), St. Mary's Hospital (US), Inje University Haeundae Paik Hospital (KR), CHA University Bundang Medical Center (KR), Kangdong Sacred Heart Hospital (KR), CHA University (KR), Yeungnam University Medical Center (KR), Hallym University Dongtan Sacred Heart Hospital (KR), Hallym University Sacred Heart Hospital (KR), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Yonsei University Mirae Campus (KR), Ajou University Medical Center (KR), Dong-A University (KR), Keimyung University (KR), Yeungnam University (KR), Ajou University (KR), Catholic University of Korea (KR), Kosin University (KR)
Ministry of Food and Drug Safety, National Research Foundation of Korea
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon